Ken Abrams, MD is Vice President of Clinical Development at Talaris Therapeutics. Prior to joining Talaris, Ken advanced through roles of increasing responsibility at Novartis from 1997 to 2019 in US and global medical affairs as well as global clinical development. His experience in small molecule and monoclonal antibody development spans multiple disciplines including pediatric rare and adult autoinflammatory/autoimmune conditions, dermatology, respiratory medicine, bone metabolism, and kidney transplantation. Before joining Novartis, Dr. Abrams was an internist at a Boston University-associated group practice and prior to that worked at Kaiser Permanente in the Bay Area while completing a dermatology research fellowship at UCSF. Ken completed his internal medicine residency at George Washington University and earned his M.D. at Tulane University School of Medicine.